ClinicalTrials.gg
CompletedNCT00680953DIRECTUpdated Mar 12, 2015Results posted

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

A Phase 3 interventional study of Denosumab and Placebo in Osteoporosis, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 4 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-12.

Sponsored by Daiichi Sankyo Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,262
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
3rd of 64
1,262 · median 90
Started
2008
the only one that year
Phase 3
24 of 64
2 open now
Registered
12th of 64
by date

Among the 64 studies testing denosumab in Osteoporosis, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 24 in phase 3, and was the 12th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Involutional ( and senile) osteoporosis with prevalent fragility vertebral fractures

Exclusion criteria

Exclusion Criteria:

  • Any underlying condition,(other than BMD) that might have resulted in abnormal bone metabolism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,262 participants (actual)

Study arms

  • Experimental
    1

    Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).

    Drug: Denosumab

  • Placebo comparator
    2

    Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).

    Drug: Placebo

  • Active comparator
    3

    Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).

    Drug: Alendronate sodium hydrate

Interventions

  • Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

  • DrugPlacebo

    Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

  • Oral tablet once a week for 24 months

06

What researchers measure

Primary outcomes

  1. Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo

    Time frame: Baseline to 24 months

Secondary outcomes

  1. The Percentage of Non-vertebral Fractures

    The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures

    Time frame: Baseline to 24 Months

  2. Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.

    The results are expressed as a percentage by Kaplan-Meier estimate.

    Time frame: Baseline to 24 Months

07

Results

Posted Feb 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneDenosumabPlaceboAlendronate
Started500511251
Completed414416204
Not completed869547

Outcome measures

PrimaryIncidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo
Time frame:
Baseline to 24 months
Reported as:
Mean · Vertebral fractures
Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo
Vertebral fracturesDenosumabPlaceboAlendronate
Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo3.6 (2.2 to 5.8)10.3 (7.8 to 13.5)7.2 (4.6 to 11.4)
Statistical analysis
  • Denosumab vs Placebo · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.343 · 95% CI 0.194 to 0.606
SecondaryThe Percentage of Non-vertebral Fractures

The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures

Time frame:
Baseline to 24 Months
Reported as:
Number · percentage of participants
The Percentage of Non-vertebral Fractures
percentage of participantsDenosumabPlaceboAlendronate
The Percentage of Non-vertebral Fractures4.1 (2.6 to 6.6)4.1 (2.6 to 6.5)2.7 (1.2 to 5.9)
Statistical analysis
  • Denosumab vs Placebo · Log Rank · p = 0.9951
SecondaryPercentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.

The results are expressed as a percentage by Kaplan-Meier estimate.

Time frame:
Baseline to 24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.
percentage of participantsDenosumabPlaceboAlendronate
Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.0.0 (0.0 to 0.0)0.5 (0.1 to 1.9)0.0 (0.0 to 0.0)
Statistical analysis
  • Denosumab vs Placebo · Log Rank · p = 0.1568

Adverse events

Collected over Baseline to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab—65/475 (13.7%)475/475 (100%)
Placebo—68/481 (14.1%)481/481 (100%)
Alendronate—30/242 (12.4%)242/242 (100%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventDenosumabPlaceboAlendronate
CataractEye disorders2/4757/4815/242
OsteoarthritisMusculoskeletal and connective tissue disorders3/4751/4813/242
Colonic polypGastrointestinal disorders1/4755/4811/242
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders4/4750/4811/242
PneumoniaInfections and infestations0/4751/4812/242
VertigoEar and labyrinth disorders1/4750/4812/242
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders3/4753/4811/242
Subarachnoid haemorrhageNervous system disorders3/4751/4810/242
Cerebral infarctionNervous system disorders3/4750/4810/242
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4753/4810/242
Most frequent other events
Showing 10 of 22
Most frequent other events
EventDenosumabPlaceboAlendronate
NasopharyngitisInfections and infestations211/475203/48193/242
ContusionInjury, poisoning and procedural complications80/47574/48154/242
OsteoarthritisMusculoskeletal and connective tissue disorders77/47543/48137/242
Dental cariesGastrointestinal disorders73/47564/48129/242
Back painMusculoskeletal and connective tissue disorders69/47560/48128/242
ConstipationGastrointestinal disorders49/47537/48121/242
PeriodontitisGastrointestinal disorders41/47527/48116/242
EczemaSkin and subcutaneous tissue disorders39/47541/48116/242
HypertensionVascular disorders39/47536/48111/242
ArthralgiaMusculoskeletal and connective tissue disorders38/47530/48117/242

Baseline characteristics

The demography information shows the number of participants included in the full analysis set (FAS) for efficacy analyses, which includes all randomized subjects except for those who did not have osteoporosis, did not receive the investigational product, or had no available efficacy data after the first dose of the investigational product.

Age, Continuous
Age, Continuous(years)DenosumabPlaceboAlendronateTotal
Mean69.9 ± 7.3669.0 ± 7.6770.2 ± 7.3169.6 ± 7.49
Sex: Female, Male
Sex: Female, Male(Participants)DenosumabPlaceboAlendronateTotal
Female4494562301135
Male23241259
Region of Enrollment
Region of Enrollment(participants)DenosumabPlaceboAlendronateTotal
Japan4724802421194
the number of participants with vertebral fractures
the number of participants with vertebral fractures(Participants)DenosumabPlaceboAlendronateTotal
Number4664712371174
08

Study locations

4 sites
  • Fukuoka, Japan
  • Osaka, Japan
  • Sapporo, Japan
  • Tokyo, Japan
09

References and documents

Publications

  • Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014 Jul;99(7):2599-607. doi: 10.1210/jc.2013-4175. Epub 2014 Mar 19. PubMed 24646104 ↗
  • Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18. PubMed 25403903 ↗
  • Okubo N, Matsui S, Matsumoto T, Sugimoto T, Hosoi T, Osakabe T, Watanabe K, Takami H, Shiraki M, Nakamura T. Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis. Calcif Tissue Int. 2020 Dec;107(6):559-566. doi: 10.1007/s00223-020-00750-y. Epub 2020 Aug 25. PubMed 32839843 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2008
First posted
May 20, 2008
Start
May 2008
Primary completionActual
Jun 2012
CompletionActual
Jul 2012
Results first posted
Feb 26, 2014
Last update
Mar 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00680953
Responsible party
Sponsor
First posted
May 20, 2008
Start date
May 2008
Primary completion
Jun 2012
Completion
Jul 2012
Results posted
Feb 26, 2014
Last update
Mar 12, 2015

Study contacts

Daiichi Sankyo
study chair · R&D Division, Daiichi Sankyo Co., Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion